Claims Scope:

Patent issued May 1, 2021. 

Sequence agnostic claims – Composition only.   

Sequence agnostic claims targeting FDPS, further requiring a helper and envelope.  Further claims to compositions (vectors and particles) that require 80%-95% sequence identity SEQ ID NOs: 1-4 (shRNA) and SEQ ID Nos: 5-10 (microRNA) that target FDPS. Combination claims also include amino bisphosphonates. 

No limitation to activating GD T cells or infecting a cancer cell.